Literature DB >> 22109081

Bee venom in cancer therapy.

Nada Oršolić1.   

Abstract

Bee venom (BV) (api-toxin) has been widely used in the treatment of some immune-related diseases, as well as in recent times in treatment of tumors. Several cancer cells, including renal, lung, liver, prostate, bladder, and mammary cancer cells as well as leukemia cells, can be targets of bee venom peptides such as melittin and phospholipase A2. The cell cytotoxic effects through the activation of PLA2 by melittin have been suggested to be the critical mechanism for the anti-cancer activity of BV. The induction of apoptotic cell death through several cancer cell death mechanisms, including the activation of caspase and matrix metalloproteinases, is important for the melittin-induced anti-cancer effects. The conjugation of cell lytic peptide (melittin) with hormone receptors and gene therapy carrying melittin can be useful as a novel targeted therapy for some types of cancer, such as prostate and breast cancer. This review summarizes the current knowledge regarding potential of bee venom and its compounds such as melittin to induce cytotoxic, antitumor, immunomodulatory, and apoptotic effects in different tumor cells in vivo or in vitro. The recent applications of melittin in various cancers and a molecular explanation for the antiproliferative properties of bee venom are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22109081     DOI: 10.1007/s10555-011-9339-3

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  99 in total

Review 1.  Latarcins: versatile spider venom peptides.

Authors:  Peter V Dubovskii; Alexander A Vassilevski; Sergey A Kozlov; Alexey V Feofanov; Eugene V Grishin; Roman G Efremov
Journal:  Cell Mol Life Sci       Date:  2015-08-19       Impact factor: 9.261

2.  Melittin modulates keratinocyte function through P2 receptor-dependent ADAM activation.

Authors:  Anselm Sommer; Anja Fries; Isabell Cornelsen; Nancy Speck; Friedrich Koch-Nolte; Gerald Gimpl; Jörg Andrä; Sucharit Bhakdi; Karina Reiss
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

3.  Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer.

Authors:  Zidan Jin; Jie Yao; Nianlin Xie; Libo Cai; Shuai Qi; Zhan Zhang; Bai Li
Journal:  J Immunol Res       Date:  2018-05-03       Impact factor: 4.818

4.  Anti-cancer effect of bee venom on human MDA-MB-231 breast cancer cells using Raman spectroscopy.

Authors:  Gyeong Bok Jung; Jeong-Eun Huh; Hyo-Jung Lee; Dohyun Kim; Gi-Ja Lee; Hun-Kuk Park; Jae-Dong Lee
Journal:  Biomed Opt Express       Date:  2018-10-25       Impact factor: 3.732

Review 5.  Pore-forming bacterial toxins and antimicrobial peptides as modulators of ADAM function.

Authors:  Karina Reiss; Sucharit Bhakdi
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

6.  Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.

Authors:  Jonathan O Martinez; Michael Evangelopoulos; Rohan Bhavane; Stefania Acciardo; Francesco Salvatore; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

7.  The anti-hepatocellular carcinoma activity of Mel-P15 is mediated by natural killer cells.

Authors:  Tao Xu; Tongxing Cui; Lipan Peng; Shuai Kong; Jianqiang Zou; Xingsong Tian
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

8.  TT-1, an analog of melittin, triggers apoptosis in human thyroid cancer TT cells via regulating caspase, Bcl-2 and Bax.

Authors:  Lanlan Wan; Daqi Zhang; Jinnan Zhang; Liqun Ren
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

Review 9.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

10.  Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin.

Authors:  Goran Gajski; Tamara Čimbora-Zovko; Sanjica Rak; Maja Osmak; Vera Garaj-Vrhovac
Journal:  Cytotechnology       Date:  2015-04-28       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.